Breast cancer claims approximately 670,000 lives annually. According to data from the World Health Organization (WHO), breast cancer was the most common cancer in women among 157 out of 185 countries in 2022, with over 2 million women diagnosed each year. Early detection and targeted drug therapy are crucial for combating this deadly disease. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the treatment of early-stage breast cancer when used in combination with hormone therapy. This approval is beneficial for patients concerned about cancer recurrence. Kisqali works by inhibiting proteins CDK4/6, which are critical for cancer cell growth and division. Administered orally as a pill, Kisqali is prescribed for a three-week cycle followed by a one-week break, to be continued for three years, and can be taken with or without food.Kisqali Edition: Side effects

Common side effects of Kisqali medication include a decrease in white blood cell count, known as neutropenia. Neutropenia happens when there are reduced levels of neutrophils in the blood, which are important for fighting infections in the body. Another potential side effect of Kisqali is liver complications and interstitial lung disease/pneumonitis.

Breast Cancer: Warning signs that should not be overlooked